Coherus Oncology, Inc. (CHRS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.01-3.81%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Coherus Oncology, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	18.22M
EPS	—	-0.221
Annual ending 2026-12-31
Revenue	—	60.81M
EPS	—	-0.885
Annual ending 2027-12-31
Revenue	—	100.37M
EPS	—	-0.762

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
LOQTORZI net revenue growth	A primary condition in Coherus Oncology, Inc.'s published investment case. The stated target is >= $42 million revenue in FY26.	Improving	LOQTORZI revenue falls below $42 million in FY26	Revenue: $14.307M FY2026-Q2; GAAP. Published target: >= $42 million revenue in FY26. Target period is not explicitly aligned with this observation. Source published Aug 5, 202614,307,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: da4864ca-70f2-4894-b4e5-bcd0b679fcac. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. LOQTORZI net revenue grew from $11.8 million in 2026-Q1 to $13.6 million in 2026-Q2 (+15%), and from $10.0 million in 2025-Q2 to $13.6 million in 2026-Q2 (+37%). Management emphasizes growth via new patient starts and therapy duration, and the trajectory is delivering. Delivery assessment Oct 24, 2026
Stable management and accounting practices	A supporting condition in Coherus Oncology, Inc.'s published investment case. The stated target is No further negative accounting or regulatory events in next 12 months.	Intact	New negative legal or accounting events occur	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Profitability and free cash flow	A primary condition in Coherus Oncology, Inc.'s published investment case. The stated target is Reduce losses and improve free cash flow toward breakeven by FY28.	Improving	Losses widen or free cash flow remains negative beyond FY28	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total company revenue growth	A primary condition in Coherus Oncology, Inc.'s published investment case. The stated target is >= $150 million revenue in FY28.	Improving	Total revenue falls below $150 million in FY28	Revenue: $14.307M FY2026-Q2; GAAP. Published target: >= $150 million revenue in FY28. Target period is not explicitly aligned with this observation. Source published Aug 5, 202614,307,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: da4864ca-70f2-4894-b4e5-bcd0b679fcac. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. LOQTORZI net revenue grew from $11.8 million in 2026-Q1 to $13.6 million in 2026-Q2 (+15%), and from $10.0 million in 2025-Q2 to $13.6 million in 2026-Q2 (+37%). Management emphasizes growth via new patient starts and therapy duration, and the trajectory is delivering. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.10B

$0.10B → $0.10B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$100,070,600	1 / 5
2026-07-25	Unavailable	$100,070,600	1 / 5
2026-07-26	Unavailable	$100,070,600	1 / 5
2026-07-27	Unavailable	$100,070,600	1 / 5
2026-07-28	Unavailable	$100,070,600	1 / 5
2026-07-29	Unavailable	$100,070,600	1 / 5
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	$100,070,600	1 / 5
2026-08-01	Unavailable	$100,070,600	1 / 5
2026-08-02	Unavailable	$100,070,600	1 / 5
2026-08-03	Unavailable	$100,070,600	1 / 5
2026-08-04	Unavailable	Unavailable	2 / 4
2026-08-05	Unavailable	Unavailable	2 / 4
2026-08-06	Unavailable	Unavailable	2 / 4
2026-08-07	Unavailable	Unavailable	2 / 4
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	Unavailable	2 / 4
2026-08-10	Unavailable	Unavailable	2 / 4
2026-08-11	Unavailable	Unavailable	2 / 4
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	$100,223,640	2 / 7
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	$88,156,100	2 / 5
2026-08-17	Unavailable	$88,156,100	2 / 5
2026-08-18	Unavailable	$88,156,100	2 / 5
2026-08-19	Unavailable	$88,156,100	2 / 5
2026-08-20	Unavailable	$100,366,862	2 / 5
2026-08-21	Unavailable	$100,366,862	2 / 5
2026-08-22	Unavailable	$100,366,862	2 / 5
2026-08-23	Unavailable	$100,366,862	2 / 5
2026-08-24	Unavailable	$100,366,862	2 / 5
2026-08-25	Unavailable	$100,366,862	2 / 5
2026-08-26	Unavailable	$100,366,862	2 / 5
2026-08-27	Unavailable	$100,366,862	2 / 5
2026-08-28	Unavailable	$100,366,862	2 / 5
2026-08-29	Unavailable	$100,366,862	2 / 5
2026-08-30	Unavailable	$100,366,862	2 / 5
2026-08-31	Unavailable	$100,366,862	2 / 5
2026-09-01	Unavailable	$100,366,862	2 / 5
2026-09-02	Unavailable	$100,366,862	2 / 5
2026-09-03	Unavailable	$100,366,862	2 / 5
2026-09-04	Unavailable	$100,366,862	2 / 5
2026-09-05	Unavailable	$100,366,862	2 / 5
2026-09-06	Unavailable	$100,366,862	2 / 5
2026-09-07	Unavailable	$100,366,862	2 / 5
2026-09-08	Unavailable	$100,366,862	2 / 5
2026-09-09	Unavailable	$100,366,862	2 / 5
2026-09-10	Unavailable	$100,366,862	2 / 5
2026-09-11	Unavailable	$100,366,862	2 / 5
2026-09-12	Unavailable	$100,366,862	2 / 5
2026-09-13	Unavailable	$100,366,862	2 / 5
2026-09-14	Unavailable	$100,366,862	2 / 5
2026-09-15	Unavailable	$100,366,862	2 / 5
2026-09-16	Unavailable	$100,366,862	2 / 5
2026-09-17	Unavailable	$100,366,862	2 / 5
2026-09-18	Unavailable	$100,366,862	2 / 5
2026-09-19	Unavailable	$100,366,862	2 / 5
2026-09-20	Unavailable	$100,366,862	2 / 5
2026-09-21	Unavailable	$100,366,862	2 / 5
2026-09-22	Unavailable	$100,366,862	2 / 5
2026-09-23	Unavailable	$100,366,862	2 / 5
2026-09-24	Unavailable	$100,366,862	2 / 5
2026-09-25	Unavailable	$100,366,862	2 / 5
2026-09-26	Unavailable	$100,366,862	2 / 5
2026-09-27	Unavailable	$100,366,862	2 / 5
2026-09-28	Unavailable	$100,366,862	2 / 5
2026-09-29	Unavailable	$100,366,862	2 / 5
2026-09-30	Unavailable	$100,366,862	2 / 5
2026-10-01	Unavailable	$100,366,862	2 / 5
2026-10-02	Unavailable	$100,366,862	2 / 5
2026-10-03	Unavailable	$100,366,862	2 / 5
2026-10-04	Unavailable	$100,366,862	2 / 5
2026-10-05	Unavailable	$100,366,862	2 / 5
2026-10-06	Unavailable	$100,366,862	2 / 5
2026-10-07	Unavailable	$100,366,862	2 / 5
2026-10-08	Unavailable	$100,366,862	2 / 5
2026-10-09	Unavailable	$100,366,862	2 / 5
2026-10-10	Unavailable	$100,366,862	2 / 5
2026-10-11	Unavailable	$100,366,862	2 / 5
2026-10-12	Unavailable	$100,366,862	2 / 5
2026-10-13	Unavailable	$100,366,862	2 / 5
2026-10-14	Unavailable	$100,366,862	2 / 5
2026-10-15	Unavailable	$100,366,862	2 / 5
2026-10-16	Unavailable	$100,366,862	2 / 5
2026-10-17	Unavailable	$100,366,862	2 / 5
2026-10-18	Unavailable	$100,366,862	2 / 5
2026-10-19	Unavailable	$100,366,862	2 / 5
2026-10-20	Unavailable	$100,366,862	2 / 5
2026-10-21	Unavailable	$100,366,862	2 / 5
2026-10-22	Unavailable	$100,366,862	2 / 5
2026-10-23	Unavailable	$100,366,862	2 / 5
2026-10-24	Unavailable	$100,366,862	2 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	5	1
2026-10-01	5	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

LOQTORZI net revenue growthRevenue: $14.307M
Stable management and accounting practicesQualitative condition
Profitability and free cash flowDirect metric needs a verified mapping
Total company revenue growthRevenue: $14.307M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-61.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Coherus Oncology, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CHRS is a high-risk, loss-making biotech business with growth tied to its commercial product and clinical programs. Its multi-year view is intact, though the recent signal shifted from mildly favorable to mixed and management execution has been volatile.

What's priced into Coherus Oncology, Inc.

The valuation is described as cheap versus peers, and the priced-in tag is justified, with no fragility gates triggered. However, valuation-model confidence is low, so the expectations gap is uncertain rather than a firm measure of what the market assumes.

What the fundamentals likely do

Near term, LOQTORZI revenue growth and lower expenses support the business, while the continuing loss has narrowed year over year. The next-quarter earnings miss risk is elevated, and a guidance cut would be a meaningful setback; clinical progress is mixed, with multiple readouts expected in the second half of 2026.

What Coherus Oncology, Inc. hinges on

Over the multi-year view, the thesis depends on continued LOQTORZI growth, progress in tagmokitug and casdozokitug trials, and further control of operating losses. Near term, guidance and the earnings outlook matter, while weaker jobs data could pressure cyclical names and strong results from healthcare peers could support sector momentum.